Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

PENG Jing; LIU Wei

doi:10.3969/j.issn.1006-0111.2015.06.008

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 33 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2015 > 33(6): 508-512

PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008

Citation:

PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

doi: 10.3969/j.issn.1006-0111.2015.06.008

PENG Jing¹,
LIU Wei^2
,

1.
No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China
2.
No. 88 Hospital of PLA, Taian 271000, China

Received Date: 2014-05-16
Rev Recd Date: 2015-01-20

Abstract

Drug metabolism and drug-drug interactions were associated with the single nucleotide polymorphisms of CYP. The relationship between CYP2C19 polymorphisms and metabolism as well as interactions of proton pump inhibitors, voriconazole and clopidogrel were reviewed to provide evidence for personalized medication.
- CYP2C19,
- polymorphism,
- proton pump inhibitor,
- voriconazole,
- clopidogrel

References

[1]	吴敏良,吴晓虹,陈枢青. 细胞色素P4502C19 在中国汉族人群不同组织中的分布差异研究[J] .中国药学杂志,2005,40(3):215-218.
[2]	Bertilsson L,Lou YC, Du YU,et al.Pronounced difference between native Chinese and Swedish populations in the polymorphichydroxylation of debrisoquin and S-mephenytoin[J]. Clin Pharmacol Ther, 1992,51(4):388-397.
[3]	Blaisdell J,Mohrenweiser H,Jackson J,et al.Identification and functional characterization of new potentially defective alleles of human CYP2C19[J]. Pharmacogenetics, 2002,12(9):703-711.
[4]	Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J] . Clin Pharmacol Ther,2006,79(1):103-113.
[5]	Xie HG,Huang SL,Xu ZH,et al.Evidence for the effect of gender on activity of S-mephenytoin in a Chinese population[J]. Pharmacogenetics, 1997,7(2):115-119.
[6]	Wedlund PJ,Aslanian WS,McAllister CB,et al.Mephenytoin hydroxylation deficiency in caucasians: frequency of a new oxidative drug metabolism polymorphism [J]. Clin Pharmacol Ther,1984,36(6):773-780.
[7]	Jacquehnes SM, PhamlJ DB, John WF.Determination of CYP2C19 phenotype in black Americans wit homeprazole: correlation with genotype [J]. Clin Pharmacol Ther,1996,60(2):138-144.
[8]	Zhang YX, Wei SJ, Yang XY,et al. Effects of genetic polymorphisms of CYP2C192/3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2014,52(10):850-855.
[9]	姜英杰,李瑜元, 聂玉强, 等. 雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19 基因多态性的关系[J]. 广州医学院学报, 2004, 32(3): 22-25.
[10]	Sezgin O,Barlas IO,Uçbilek E,et al.Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective[J].Acta Gastroenterol Belg,2014,77(1):3-7.
[11]	Lee JY,Kim N,Kim MS,et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance[J]. Dig Dis Sci,2014,59(6):1235-1243.
[12]	John J,Lima,Jason EL,et al.Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children[J]. Pediatry,2013,163(3):686-691.[13] Varenhorst C,James S, Erlinge D, et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not rasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14):1744-1752.
[13]	Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina[J].J Cardiol,2015,65(6):494-500.
[14]	谢婧,杨莉萍,刘瑶,等.CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析[J]. 中国药房,2012,23(28):2618-2621.
[15]	Crepeau AZ, Moseley BD, Wirrell EC.Specific safety and tolerability considerations in the use of anticonvulsant medications in children[J].Drug Health Patient Saf,2012,4: 39-54.
[16]	Kouga T, Shimbo H, Iai M,et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome[J]. Brain Dev, 2015,37(2):243-249.
[17]	de Leon J.The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19[J].Clin Psychopharm,2007,27(3):241-245.
[18]	王瓅珏,唐惠林,段京莉. CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价[J]. 中国临床药理学杂志,2011,29(8):607-611.
[19]	Zonios D,Yamazaki H,Murayama N,et al.Voriconazole metabolism, toxicity and the effect of cytochrome P450 2C19 genotype [J].J Infect Dis,2014,209(12):1941-1948.
[20]	Choi CI,Bae JW,Lee YJ,et al.Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics[J]. J Clin Psychopharmacol, 2014,34(1):139-142.[22] Nastasi-Catanese JA,Padilla-Gutiérrez JR,Valle Y, et al.Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response[J]. Genet Mol Res,2013,12(4):4413-4421.
[21]	Sibbing D,Morath T,Stegherr J,et al.Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101(4):714-719.
[22]	Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor[J].Arch Intern Med, 2010,170(8):704-710.[25] 曲彩红,黎小妍. 伏立康唑与奥美拉唑可能的不良相互作用致肌病及肝功能恶化[J]. 药物不良反应杂志,2011,13(6): 374-377.
[23]	Kim DY,Park HJ,Lee YJ.Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections[J]. Int J Clin Pharmacol Ther,2014,52(3):209-216.
[24]	Simon T, Steg PG, Gilard M, et al.Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P4502C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute st-elevation and non-st-elevation myocardial infarction (FAST-MI) registry[J]. Circulation,2011,123(5):474-482.
[25]	Furuta T,Iwaki T,Umemura K. Influences of different proton pump inhibitors on the antiplatelet function of clopidogrel in relation to CYP2C19 genotypes[J] . Br J Clin Pharmacol, 2010, 70(3):383-392.
[26]	Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2) [J].JACC Cardiovasc Interv,2011,4(4):392-402.
[27]	Wallentin L,James S,Storey RF,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
[28]	Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation,2009, 119(9):2553-2560.
[29]	Erlinge D,James S,Duvvuru S,et al.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease[J].Thromb Haemost,2014,111(5):943-950.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3770) PDF downloads(275) Cited by()

Proportional views

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

1. No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China

2. No. 88 Hospital of PLA, Taian 271000, China

Received Date: 2014-05-16

Rev Recd Date: 2015-01-20

Key words:

Abstract: Drug metabolism and drug-drug interactions were associated with the single nucleotide polymorphisms of CYP. The relationship between CYP2C19 polymorphisms and metabolism as well as interactions of proton pump inhibitors, voriconazole and clopidogrel were reviewed to provide evidence for personalized medication.

HTML

Reference (29)

[1]	吴敏良,吴晓虹,陈枢青. 细胞色素P4502C19 在中国汉族人群不同组织中的分布差异研究[J] .中国药学杂志,2005,40(3):215-218.
[2]	Bertilsson L,Lou YC, Du YU,et al.Pronounced difference between native Chinese and Swedish populations in the polymorphichydroxylation of debrisoquin and S-mephenytoin[J]. Clin Pharmacol Ther, 1992,51(4):388-397.
[3]	Blaisdell J,Mohrenweiser H,Jackson J,et al.Identification and functional characterization of new potentially defective alleles of human CYP2C19[J]. Pharmacogenetics, 2002,12(9):703-711.
[4]	Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J] . Clin Pharmacol Ther,2006,79(1):103-113.
[5]	Xie HG,Huang SL,Xu ZH,et al.Evidence for the effect of gender on activity of S-mephenytoin in a Chinese population[J]. Pharmacogenetics, 1997,7(2):115-119.
[6]	Wedlund PJ,Aslanian WS,McAllister CB,et al.Mephenytoin hydroxylation deficiency in caucasians: frequency of a new oxidative drug metabolism polymorphism [J]. Clin Pharmacol Ther,1984,36(6):773-780.
[7]	Jacquehnes SM, PhamlJ DB, John WF.Determination of CYP2C19 phenotype in black Americans wit homeprazole: correlation with genotype [J]. Clin Pharmacol Ther,1996,60(2):138-144.
[8]	Zhang YX, Wei SJ, Yang XY,et al. Effects of genetic polymorphisms of CYP2C192/3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2014,52(10):850-855.
[9]	姜英杰,李瑜元, 聂玉强, 等. 雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19 基因多态性的关系[J]. 广州医学院学报, 2004, 32(3): 22-25.
[10]	Sezgin O,Barlas IO,Uçbilek E,et al.Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective[J].Acta Gastroenterol Belg,2014,77(1):3-7.
[11]	Lee JY,Kim N,Kim MS,et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance[J]. Dig Dis Sci,2014,59(6):1235-1243.
[12]	John J,Lima,Jason EL,et al.Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children[J]. Pediatry,2013,163(3):686-691.[13] Varenhorst C,James S, Erlinge D, et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not rasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14):1744-1752.
[13]	Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina[J].J Cardiol,2015,65(6):494-500.
[14]	谢婧,杨莉萍,刘瑶,等.CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析[J]. 中国药房,2012,23(28):2618-2621.
[15]	Crepeau AZ, Moseley BD, Wirrell EC.Specific safety and tolerability considerations in the use of anticonvulsant medications in children[J].Drug Health Patient Saf,2012,4: 39-54.
[16]	Kouga T, Shimbo H, Iai M,et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome[J]. Brain Dev, 2015,37(2):243-249.
[17]	de Leon J.The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19[J].Clin Psychopharm,2007,27(3):241-245.
[18]	王瓅珏,唐惠林,段京莉. CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价[J]. 中国临床药理学杂志,2011,29(8):607-611.
[19]	Zonios D,Yamazaki H,Murayama N,et al.Voriconazole metabolism, toxicity and the effect of cytochrome P450 2C19 genotype [J].J Infect Dis,2014,209(12):1941-1948.
[20]	Choi CI,Bae JW,Lee YJ,et al.Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics[J]. J Clin Psychopharmacol, 2014,34(1):139-142.[22] Nastasi-Catanese JA,Padilla-Gutiérrez JR,Valle Y, et al.Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response[J]. Genet Mol Res,2013,12(4):4413-4421.
[21]	Sibbing D,Morath T,Stegherr J,et al.Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101(4):714-719.
[22]	Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor[J].Arch Intern Med, 2010,170(8):704-710.[25] 曲彩红,黎小妍. 伏立康唑与奥美拉唑可能的不良相互作用致肌病及肝功能恶化[J]. 药物不良反应杂志,2011,13(6): 374-377.
[23]	Kim DY,Park HJ,Lee YJ.Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections[J]. Int J Clin Pharmacol Ther,2014,52(3):209-216.
[24]	Simon T, Steg PG, Gilard M, et al.Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P4502C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute st-elevation and non-st-elevation myocardial infarction (FAST-MI) registry[J]. Circulation,2011,123(5):474-482.
[25]	Furuta T,Iwaki T,Umemura K. Influences of different proton pump inhibitors on the antiplatelet function of clopidogrel in relation to CYP2C19 genotypes[J] . Br J Clin Pharmacol, 2010, 70(3):383-392.
[26]	Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2) [J].JACC Cardiovasc Interv,2011,4(4):392-402.
[27]	Wallentin L,James S,Storey RF,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
[28]	Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation,2009, 119(9):2553-2560.
[29]	Erlinge D,James S,Duvvuru S,et al.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease[J].Thromb Haemost,2014,111(5):943-950.

Message Board

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

doi: 10.3969/j.issn.1006-0111.2015.06.008

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views